From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD25
Clinical data
Trade names Simulect
AHFS/ monograph
  • AU: D
  • US: B (No risk in non-human studies)
Pharmacokinetic data
Biological half-life 7.2 days
CAS Number 152923-56-3 YesY
ATC code L04AC02
DrugBank DB00074 YesY
UNII 9927MT646M YesY
Chemical data
Formula C6378H9844N1698O1997S48
Molecular mass 143801.3 g/mol
 N (what is this?)  (verify)

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.


Basiliximab is an immunosuppresant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of Lichen Planus have been successfully treated with Basiliximab as an alternative therapy to Cyclosporine, with a dose of 20 mg every 4 days. No short-term side effects have been reported [2]

Mechanism of action[edit]

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]

Physical and chemical properties[edit]

It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]


It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[4][5]

References and notes[edit]

  1. ^ MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
  2. ^ A.D. Katsambas, T.M. Lotti European handbook of dermatological treatments 2nd edition, 2003, page 291, ISBN 3-540-00878-0
  3. ^ a b Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013 Jul;26(7):662-72. PMID 23279211
  4. ^ a b c Basiliximab label
  5. ^ Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.